Meeuwisse Cory, Morgan Catherine J, Samuel Susan, Alexander R Todd, Rodriguez-Lopez Sara
Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
Division of Nephrology, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
Can J Kidney Health Dis. 2022 Mar 11;9:20543581221079959. doi: 10.1177/20543581221079959. eCollection 2022.
There is known practice variation in the treatment of frequently relapsing, steroid-dependent, and steroid-resistant nephrotic syndrome in children. Rituximab is an emerging therapy for difficult-to-treat nephrotic syndrome; however, there are no clear treatment guidelines. We therefore hypothesized that a wide variety of approaches to this therapy exist.
To evaluate when and how rituximab is used for the treatment of childhood nephrotic syndrome in Canada.
An online survey was used.
Canadian pediatric nephrologists.
A cross-sectional survey was distributed across Canada through the Canadian Association of Pediatric Nephrologists (CAPN) to evaluate rituximab treatment practices.
Of a total of 20 responses, 19 (95%) use rituximab in the treatment of nephrotic syndrome, usually as a third or fourth agent. For the number of rituximab doses, the majority (68%) uses 2 doses each time they use it. Eighteen respondents (90%) measure B cells when using this medication, mostly monthly (50%) or every 3 months (39%). Respondents were administered additional doses of rituximab prophylactically (74%) or at first relapse (47%). Long-term drug safety and drug funding were identified as the main barriers to rituximab use.
This survey represents the practice styles of physicians in a single country, and there is a nonresponse bias of 63%. Also, associations were not calculated.
Among Canadian pediatric nephrologists, rituximab use for nephrotic syndrome appears to be increasing, but significant practice variations remain, including approaches to B-cell monitoring. It is reserved mostly for second-line and third-line use due to cost, funding issues, and residual uncertainty regarding long-term safety. Understanding these critical areas of practice uncertainty is a first step to optimize treatment of nephrotic syndrome in children.
在儿童频繁复发、依赖类固醇及对类固醇耐药的肾病综合征治疗中,存在已知的治疗差异。利妥昔单抗是一种用于治疗难治性肾病综合征的新兴疗法;然而,目前尚无明确的治疗指南。因此,我们推测存在多种针对该疗法的治疗方法。
评估加拿大何时以及如何使用利妥昔单抗治疗儿童肾病综合征。
采用在线调查。
加拿大儿科肾病学家。
通过加拿大儿科肾病学家协会(CAPN)在加拿大开展横断面调查,以评估利妥昔单抗的治疗实践。
在总共20份回复中,19份(95%)使用利妥昔单抗治疗肾病综合征,通常作为第三或第四种药物。对于利妥昔单抗的剂量,大多数(68%)每次使用时使用2剂。18名受访者(90%)在使用该药物时检测B细胞,大多为每月(50%)或每3个月(39%)检测一次。受访者预防性(74%)或在首次复发时(47%)给予额外剂量的利妥昔单抗。长期药物安全性和药物资金被确定为使用利妥昔单抗的主要障碍。
本调查仅代表一个国家医生的实践方式,且存在63%的无应答偏倚。此外,未计算相关性。
在加拿大儿科肾病学家中,利妥昔单抗用于肾病综合征的情况似乎在增加,但仍存在显著的实践差异,包括B细胞监测方法。由于成本、资金问题以及长期安全性方面仍存在不确定性,它主要保留用于二线和三线治疗。了解这些关键的实践不确定性领域是优化儿童肾病综合征治疗的第一步。